Robert Coleman is the founder of Codagenix. Codagenix has raised $49M in total funding. Latest round: Series B. Based in New York City, United States.
Robert Coleman is the Co-Founder and CEO of Codagenix, a clinical-stage biotechnology company focused on live-attenuated vaccines and viral therapies. He has guided the company through the clinical development of its intranasal COVID-19 vaccine and its RSV program. Coleman is based in the New York City metropolitan area.
Full founder directory · Investor directory · Company funding database · Fundraising library